MAIA Biotechnology, Inc. (MAIA) Form 424B3 — Oct 7, 2026
MAIA Biotechnology filed a 424B3 prospectus registering the resale of 751,879 common shares held by PoC Capital, LLC, received under an August 29, 2026 Clinical Trial Funding Agreement. MAIA will receive no proceeds from any sales, though PoC Capital agreed to provide $1,000,000 in funding toward THIO clinical study expenses. The resale shares represent roughly 1.2% of the 61,741,946 shares outstanding, a modest overhang, and sales by the stockholder are unrestricted as to price. The prospectus also references substantial doubt about MAIA's ability to continue as a going concern, noting the company will need substantial additional funding.
Key figures
- Gross Proceeds
- None to company; Selling Stockholder agreed to provide $1,000,000 in clinical trial funding
- Offering Price
- Reference closing price $1.37 per share on September 22, 2026 (no fixed offering price)
- Shares Offered
- 751879
- Shares Outstanding
- 61741946
- Options outstanding
- 16742806
- Warrants outstanding
- 13086220
- Weighted avg option price
- $2.00
- Weighted avg warrant price
- $1.92
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.